IMM-101

PRIMUS-006 study led by Professors David Chang and Jeff Evans of the University of Glasgow Phase II study is evaluating a novel combination in first-line metastatic pancreatic cancer GLASGOW, United Kingdom, June 18, 2024 (GLOBE NEWSWIRE) -- The Precision-Panc team at the University of Glasgow, with their Co-Sponsor, NHS Greater Glasgow & Clyde, today announced the opening of the Phase II PRIMUS-006 study evaluating IMM-101, a broad-spectrum immunomodulatory agent containing heat-killed, whole cell Mycobacterium obuense, in combination with gemcitabine and pembrolizumab as first-line treatment in patients with metastatic pancreatic cancer. The PRIMUS-006 study is part of the Precision-Panc Platform master protocol program, which is Co-Sponsored by NHS Greater Glasgow & Clyde and the University of Glasgow and co-ordinated by the Glasgow Oncology Clinical Trials Unit. PRIMUS-006 is endorsed by Cancer Research UK (CRUK Reference: A31505). The study is funded by Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, U.S.A., through its investigator-initiated program with provision of study drug and financial support. The study is also funded by Immodulon Therapeutics Ltd through its investigator-initiated program with provision of study drug and financial support for the study. “The opening of the Phase II PRIMUS-006 study is an important milestone in the pursuit to develop new treatment options to improve the overall outcomes in patients diagnosed with pancreatic cancer,” said Professor David Chang, principal investigator and professor of surgical oncology & honorary consultant pancreatic surgeon, Wolfson Wohl Cancer Research Centre, University of Glasgow and Glasgow Royal Infirmary. “The selection of IMM-101 to comprise part of the triplet combination reflects its potential to enhance anti-tumour activity alongside gemcitabine and pembrolizumab in patients with first-line metastatic pancreatic cancer,” said Professor Jeff Evans of the University of Glasgow and Honorary Consultant in Medical Oncology at the Beatson West of Scotland Cancer Centre, Glasgow. Pancreatic ductal adenocarcinoma (PDAC) tends to be poorly immunogenic with diminished antigen presentation and a highly immunosuppressive tumour micro-environment that further impedes the functional activation of cytotoxic T lymphocytes. Based on the ability of gemcitabine to enhance the expression of antigen-presenting molecules, its use in combination with IMM-101, a broad-spectrum immunomodulator with potential to sensitize pancreatic cancers to immune checkpoint inhibition, and pembrolizumab, MSD’s anti-PD-1 therapy, this novel combination has the potential to enhance anti-tumour efficacy in patients with first-line pancreatic cancer. “This is an exciting opportunity to be part of a high caliber pancreatic cancer research program and reflects the potential of IMM-101 to become a backbone therapy in immunologically cold tumours by enhancing the efficacy of existing anti-cancer treatment options, including chemotherapy and checkpoint inhibitors,” said Josefine Roemmler-Zehrer, MD, Associate Professor, and Chief Medical Officer of Immodulon. “We look forward to working with the Co-Sponsors NHS Greater Glasgow & Clyde and University of Glasgow, MSD and other key collaborators to support this study and advance our efforts to bring IMM-101 closer to patients diagnosed with pancreatic cancer and other solid tumours.” The Phase II PRIMUS-006 study is a single-arm clinical study evaluating IMM-101, gemcitabine and pembrolizumab as first-line combination triplet therapy in patients diagnosed with metastatic pancreatic cancer who are deemed not sufficiently fit enough to tolerate treatment consisting of two or more cytotoxic agents. As the overall objective of the study is to enhance the anti-tumour activity of immunotherapy, the primary endpoint of the study is the objective response rate as defined by RECIST 1.1. Key secondary endpoints include safety and tolerability, evaluation of progression-free survival, disease control rate and overall survival. Up to 50 patients with metastatic pancreatic ductal adenocarcinoma will be treated in the study from approximately 15-20 hospital sites in the United Kingdom. About Pancreatic Ductal Adenocarcinoma (PDAC) PDAC is the third most common cause of cancer death in the developed world. Approximately 50% of patients present with metastatic disease and most of the patients who present with resectable or locally advanced inoperable disease ultimately develop metastatic disease. Gemcitabine monotherapy has modest clinical benefit and a marginal survival advantage in patients with metastatic PDAC. Better response rates and survival can be achieved with the FOLFIRINOX regimen, and with the addition of nab-paclitaxel to gemcitabine. Nevertheless, overall survival remains disappointing with these combination cytotoxic chemotherapy regimens. Furthermore, many patients are not fit enough to tolerate these combination regimens, and these patients are invariably excluded from participation in clinical trials because of lower performance status. Consequently, these patients represent a significant unmet clinical need and are in urgent need of novel therapeutic approaches. About IMM-101 IMM-101 is a systemic, broad-spectrum immunomodulator containing heat-killed, whole cell Mycobacterium obuense, capable of generating a broad systemic innate and adaptive type 1 immune response with potential to treat immunologically ‘cold’ cancers, like pancreatic cancer. In the Phase II IMAGE-1 Study of IMM-101 in combination with gemcitabine, clinical data indicate that IMM-101 is well-tolerated and effective and that it has the potential as a first-line treatment to prolong progression-free survival in patients with advanced pancreatic ductal adenocarcinoma (PDAC) when compared to gemcitabine alone. The study data also suggest a beneficial effect on survival in patients with metastatic PDAC. Immodulon is currently prioritizing the initiation of a Bayesian adaptive pivotal study for IMM-101 in PDAC that can be expanded to evaluate IMM-101 in other immunologically ‘cold’ tumours across multiple parallel arms. About Precision-Panc Precision-Panc aims to establish a mechanism and framework to recruit and screen patients with pancreatic cancer to perform molecular profiling and evaluation of circulating biomarkers and to enable enrollment in clinical studies to accelerate therapeutic development for pancreatic cancer. The PRIMUS studies are a series of clinical trials with novel design to answer specific therapeutic questions and parallel biomarker studies. The Precision-Panc Platform is a way to accelerate stratified therapeutic development through a combination of pre-clinical work, clinical trials, and discovery. As part of the platform there will be a suite of clinical trials, with the aim to have a trial for each indication of pancreatic cancer in the future. For more information, please visit . Contacts: Josh Rappaport and William Gramig Precision AQ josh.rappaport@precisionaq.com william.gramig@precisionaq.com

UXBRIDGE, United Kingdom, April 29, 2024 (GLOBE NEWSWIRE) -- Immodulon, a late-stage clinical biotechnology company focused on developing a broad spectrum immunomodulator to improve the lives of patients suffering from difficult-to-treat cancers, today announced that Gertjan Bartlema, Chief Executive Officer, and Peter Greaney, PhD, Chief Business Officer, will participate in meetings with investors at the Wells Fargo Virtual Private Biotech Symposium on Monday, May 6, 2024. Investors are encouraged to contact their Wells Fargo representative to schedule a meeting. About Immodulon Immodulon is a late-stage clinical biotechnology company developing a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune system with the aim to significantly enhance the efficacy of a broad range of anti-cancer therapies, including chemotherapy and checkpoint inhibitors. Immodulon is developing IMM-101, a heat-killed mycobacterium obuense, as a broad-spectrum immunomodulatory agent with the potential to treat a range of difficult-to-treat tumours including those considered to be immunologically “cold,” such as pancreatic cancer. For more information, please visit www.immodulon.com. Contacts: Josh Rappaport and William GramigStern Investor Relations, Inc.josh.rappaport@sternir.comwilliam.gramig@sternir.com